Sudden death

Historic XII Federation of International Polo (FIP) World Polo Championship Concludes

Retrieved on: 
星期四, 十一月 10, 2022
GLOBE, Silver, World Polo Championship, CEO, Television, Sport, USA Team Handball, NPC, USPA, VIP, International Polo Club Palm Beach, BeIN Sports, Man, Goal, Collection, XII, Athlete, FIP, Sudden death, Awareness, Sibling, Woman, Champion, GPE, Golden Joystick Awards, History, ESPN, Video game, Nightclub, Tourism, Sports equipment, United States Polo Association

WELLINGTON, Fla., Nov. 10, 2022 (GLOBE NEWSWIRE) -- The XII Federation of International Polo (FIP) World Polo Championship, hosted by the United States Polo Association (USPA) and U.S. Polo Assn.

Key Points: 
  • WELLINGTON, Fla., Nov. 10, 2022 (GLOBE NEWSWIRE) -- The XII Federation of International Polo (FIP) World Polo Championship, hosted by the United States Polo Association (USPA) and U.S. Polo Assn.
  • Featuring top-rated polo fields, VIP experiences for both fans and players, and unrivaled corporate hospitality, the XII FIP World Polo Championship was an exceptional and unforgettable global event for players, sponsors and spectators.
  • The 2022 tournament drew the attention of the global polo community to Wellington, "the winter equestrian capital of the world," with the XII FIP World Polo Championship Opening broadcast on ESPN.
  • U.S. Polo Assn., the official brand of the United States Polo Association (USPA), served as the Official Apparel Sponsor for the XII Federation of International Polo (FIP) World Polo Championship presented by The Palm Beaches.

Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results

Retrieved on: 
星期二, 十一月 8, 2022
Myopathy, Gene, Death, Severe cognitive impairment, Brain, Company, Program, Mitochondrion, A-DNA, Conference, Security (finance), Complete Genomics, Enzyme, Muscle, INFORM, Hypoglycemia, Lethargy, U.S. Securities and Exchange Commission, Research, Lotte New York Palace Hotel, Sudden death, Patient, CEO, Metabolism, Private Securities Litigation Reform Act, Total permanent disability insurance, Protein, STRIDE, Nasdaq, Tissue, Liver, ATP, Mitochondrial disease, Exercise intolerance, PMM, Myalgia, Disorder, Adenosine triphosphate, Life, Deafness, Trial of the century, GLOBE, Investment, Guidelines International Network, Rhabdomyolysis, Encephalopathy, DNA, Home After Three Months Away, Muscle weakness, Heart, Prognosis, Pharmaceutical industry, Birth control, Nightclub, Dietary supplement

IRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September30, 2022.

Key Points: 
  • IRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September30, 2022.
  • We continued to advance our REN001 development programs during the third quarter, said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals.
  • We remain on track to announce topline data from this study in the fourth quarter of 2023.
  • Furthermore, we announced positive results from the Phase 1b study in long-chain fatty acid oxidation disorders (LC-FAOD) patients with nuclear DNA (nDNA) defects.

Global Omega 3 Supplements Market Report 2022: Growing Prevalence of Arrhythmia Driving Demand - ResearchAndMarkets.com

Retrieved on: 
星期四, 十月 20, 2022
Vitamins, Supplements, Health, Sudden death, Risk, Prevalence, CVD, Growth, Population, Organic acid, CAGR, Arrhythmia, Degenerative disease, Depression, Moyamoya disease, Fatty acid, Infarction, WHO, Center, World, Health, Centre for Disease Control and Prevention (Macau), Stroke, Awareness, Conditional sentence, World Health Organization, Anxiety, Omega-3 fatty acid, Death, Tobacco, Dietary supplement

The "Omega 3 Supplements Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Omega 3 Supplements Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The omega 3 supplements market is evaluated at US$5.875 billion for the year 2020, growing at a CAGR of 7.15% reaching a market size of US$9.497 billion by the year 2027.
  • Thus, a growing prevalence of arrhythmia may necessitate the consumption of omega 3 products as well.
  • Moreover, the increasing prevalence of arrhythmia is projected to bolster the demand for omega 3 supplements in many parts of the world.

PCA 500-- the world's most efficient and versatile 12-lead ECG, just received FDA clearance for pediatric use

Retrieved on: 
星期二, 十月 4, 2022
LQTS, Hospital, SIDS, Cardiology, Technology, ECG, CEO, EKG, Multimedia, NIH, Long QT syndrome, Digital, FDA, School, PCA, CRO, American Academy, Partnership, Child, Conference, Patient, Sudden death, We Play (EP), Medical device

LOS ANGELES, Oct. 4, 2022 /PRNewswire/ -- QT Medical announces FDA clearance of PCA 500, a resting 12-lead electrocardiogram (ECG or EKG), for use in pediatric patients.

Key Points: 
  • LOS ANGELES, Oct. 4, 2022 /PRNewswire/ -- QT Medical announces FDA clearance of PCA 500, a resting 12-lead electrocardiogram (ECG or EKG), for use in pediatric patients.
  • The development of PCA 500's pre-positioned electrodes and compact recorder was initially funded by NIH for an easy-to-use ECG specifically designed for pediatric use.
  • QT Medical will introduce PCA 500 to the pediatric market at the 2022 American Academy of Pediatrics National Conference.
  • said Dr. Ruey-Kang Chang, CEO of QT Medical, Inc.
    Two new initiatives will be announced at the pediatric market launch of PCA 500.

Boston Heart Diagnostics Launches LipoMap™: One of the Most Comprehensive Assessments of Lipid Metabolism Available

Retrieved on: 
星期一, 十月 3, 2022
Lipid, HDL, IDL, LDL, Disease, Blood, VLDL, Health, Multimedia, Death, Apolipoprotein B, Lipid metabolism, Triglyceride, Anomaly, Cardiovascular disease, Patient, CVD, Risk, NMR, Sudden death, Eurofins Scientific, Medical imaging

FRAMINGHAM, Mass., Oct. 3, 2022 /PRNewswire/ -- Boston Heart Diagnostics is pleased to announce the availability of LipoMap.

Key Points: 
  • FRAMINGHAM, Mass., Oct. 3, 2022 /PRNewswire/ -- Boston Heart Diagnostics is pleased to announce the availability of LipoMap.
  • This panel of 33 lipid, lipoprotein, and apolipoproteintests is performed via high-resolution 600 MHz nuclear magnetic resonance (NMR) and is one of the most comprehensive assessments of lipid metabolism commercially available.
  • Under-treated lipid abnormalities contribute to ongoing artery damage, a very common cause of premature cardiovascular disease (CVD) and sudden death.
  • This innovative tool from Boston Heart supports clinicians' ongoing mission to reduce this disease.

Global Frozen Seafood Markets Report 2022: A Market Valued at $16.27 Billion - Increasing Number of Health-conscious Millennials Increasing Demand - ResearchAndMarkets.com

Retrieved on: 
星期二, 九月 20, 2022
Food, Beverage, Retail, People, Income, Sudden death, Inflammation, Organic acid, COVID-19, Blood pressure, EPA, Risk, Arthritis, Population, Geography, Growth, Market share, Stroke, ADHD, Diabetes, Salmon, Pregnancy, Nutrient, Eicosapentaenoic acid, Trout, Urbanization, Food, Dementia, Overalls, Awareness, DHA, Seafood, Alzheimer's disease, Depression, CAGR, Fishing, Fast food, Convenience food, Dietary supplement

The frozen seafood market is projected to reach US$ 22.57 billion by 2028 from US$ 16.27 billion in 2022.

Key Points: 
  • The frozen seafood market is projected to reach US$ 22.57 billion by 2028 from US$ 16.27 billion in 2022.
  • Based on product type, the global frozen seafood market is segmented into frozen fish, frozen crustaceans, frozen mollusks, and others.
  • The frozen seafood market is growing significantly due to the region's increased per capita seafood consumption.
  • The growth of the frozen seafood market is also attributed to the high demand for healthy food products.

Ventricular Tachycardia (V-tach or VT) Drug Pipeline Insight Report 2022 Featuring Espero BioPharma, CTP amio Vivasc Therapeutics, Aladorian - ARMGO Pharma, & RyR2 Research Program - ResearchAndMarkets.com

Retrieved on: 
星期一, 九月 12, 2022
Health, General Health, Sudden death, II, Therapy, Ryanodine receptor 2, Route of administration, Homeostasis, Ventricular tachycardia, Ryanodine receptor, Administration, Acquisition, News, NDA, Route, Clinical trial, Technology, Cell, CPVT, Discovery, Generic drug, Medical imaging, Pharmaceutical industry

The "Ventricular Tachycardia (V-tach or VT) - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ventricular Tachycardia (V-tach or VT) - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This Ventricular Tachycardia (V-tach or VT) - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Ventricular Tachycardia (V-tach or VT) pipeline landscape.
  • A detailed picture of the Ventricular Tachycardia (V-tach or VT) pipeline landscape is provided which includes the disease overview and Ventricular Tachycardia (V-tach or VT) treatment guidelines.
  • Ventricular Tachycardia (V-tach or VT) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Pulnovo Medical Limited's PADN Technology Included in 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of PH

Retrieved on: 
星期三, 九月 7, 2022
Mortality, Treatment, European Society of Cardiology, Diagnosis, Technology, Safety, PAP, ESC Congress, Solution, ERS, LBCT, Heart failure, Late, Dog, European Respiratory Society, Physician, Medical guideline, OTM, Hypertensive emergency, PH, Breakthrough, Radiofrequency ablation, FDA, Coronavirus Scientific Advisory Board (Turkey), ESC, TCT, Cultural differences in breast cancer diagnosis and treatment, Sudden death, Patient, Guideline, Medical device, Pharmaceutical industry

The Guidelines will provide physicians and patient families with the best recommendations and the latest evidence for the diagnosis and treatment of PAH worldwide.

Key Points: 
  • The Guidelines will provide physicians and patient families with the best recommendations and the latest evidence for the diagnosis and treatment of PAH worldwide.
  • PADN is a vascular interventional ablation technology that uses radiofrequency ablation to block pulmonary intima sympathetic nerves and reduce pulmonary artery pressure to delay disease progression.
  • The Guidelines include an introduction and analysis of the PADN technique as part of the treatment for PAH.
  • The single-blind, randomized, sham-operated controlled clinical study is designed to evaluate the safety and efficacy of PADN surgery for PAH.

Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data From Innovative Science at ESMO Congress 2022

Retrieved on: 
星期二, 八月 30, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, COVID-19, Fatigue, Safety, Pain, Ari, Food and Drug Administration, Bleeding, Precision medicine, Toxicity, ESMO, Cardiac arrest, Myocardial infarction, Birth, Congress, Urinary retention, ADT, TRK, ORR, Pulmonary embolism, DASL, Adult, Moyamoya disease, Risk, Prostate cancer, Sudden death, ESCC, Patient, Bone, Female, Dyslipidemia, Hypocalcemia, Seizure, Appetite, Death, Heart failure, Food, MCRPC, FDA, Hematuria, Diabetes, Data, Docetaxel, Hyperglycemia, Consciousness, Disease, Cancer, Pneumonia, AST, Recurrence, Fatal, Rash, Radium, Quality of life, Lists of diseases, Constipation, Immunotherapy, Febrile neutropenia, ALP, Mutation, Heart, Anemia, Bilirubin, Nivolumab, ALT, Orion Corporation, Hypertension, Pregnancy, Pharmaceutical industry, Medical imaging, EU, Bayer, ARAMIS, Radium-223

Bayer will present key scientific research in oncology at the upcoming ESMO Congress 2022 from September 9-13, 2022.

Key Points: 
  • Bayer will present key scientific research in oncology at the upcoming ESMO Congress 2022 from September 9-13, 2022.
  • Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments.
  • The oncology franchise at Bayer includes six marketed products and several other assets in various stages of clinical development.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting

Retrieved on: 
星期一, 八月 29, 2022
Muscle weakness, Lists of diseases, Security (finance), Mitochondrion, Total permanent disability insurance, Safety, INFORM, Hospital, Program, Disorder, Myopathy, Gene, Rhabdomyolysis, Brain, Disease, Death, Severe cognitive impairment, Tissue, Heart, PMM, Exercise intolerance, Deafness, DNA, Prognosis, Encephalopathy, A-DNA, U.S. Securities and Exchange Commission, Myalgia, Natural history, International Network of Health Promoting Hospitals and Health Services, GLOBE, Adenosine triphosphate, Nasdaq, Population, ATP, Adult, Parallel Walk Test, Liver, Hypoglycemia, Private Securities Litigation Reform Act, Lethargy, Metabolism, Sudden death, Mitochondrial trifunctional protein deficiency, Life, Patient, Pharmaceutical industry, Dietary supplement

The poster presentations highlight the results of two recently completed clinical trials in patients with long-chain fatty acid oxidation disorders (LC-FAOD), including a successful REN001 Phase 1b study and a non-interventional natural history study.

Key Points: 
  • The poster presentations highlight the results of two recently completed clinical trials in patients with long-chain fatty acid oxidation disorders (LC-FAOD), including a successful REN001 Phase 1b study and a non-interventional natural history study.
  • Improvements in 12-minute walk test distance and physical functioning scores were observed in a subgroup of patients.
  • The poster presentations elaborate on results first announced by the company in July 2022 and highlight the unmet medical need of patients with LC-FAOD.
  • REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.